- Home
- LUCD vs GNLX Comparison
LUCD vs GNLX Comparison
Compare LUCD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- GNLX
- Stock Information
- Founded
- LUCD 2018
- GNLX 2001
- Country
- LUCD United States
- GNLX United States
- Employees
- LUCD N/A
- GNLX N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- GNLX Health Care
- Exchange
- LUCD Nasdaq
- GNLX Nasdaq
- Market Cap
- LUCD 108.0M
- GNLX 128.0M
- IPO Year
- LUCD 2021
- GNLX 2023
- Fundamental
- Price
- LUCD $1.04
- GNLX $4.67
- Analyst Decision
- LUCD Strong Buy
- GNLX Strong Buy
- Analyst Count
- LUCD 5
- GNLX 4
- Target Price
- LUCD $3.70
- GNLX $17.75
- AVG Volume (30 Days)
- LUCD 1.5M
- GNLX 131.0K
- Earning Date
- LUCD 11-12-2025
- GNLX 11-13-2025
- Dividend Yield
- LUCD N/A
- GNLX N/A
- EPS Growth
- LUCD N/A
- GNLX N/A
- EPS
- LUCD N/A
- GNLX N/A
- Revenue
- LUCD $4,360,000.00
- GNLX N/A
- Revenue This Year
- LUCD $13.90
- GNLX N/A
- Revenue Next Year
- LUCD $163.88
- GNLX N/A
- P/E Ratio
- LUCD N/A
- GNLX N/A
- Revenue Growth
- LUCD 14.74
- GNLX N/A
- 52 Week Low
- LUCD $0.75
- GNLX $1.99
- 52 Week High
- LUCD $1.80
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- LUCD 43.56
- GNLX 69.07
- Support Level
- LUCD $1.00
- GNLX $4.17
- Resistance Level
- LUCD $1.06
- GNLX $4.45
- Average True Range (ATR)
- LUCD 0.04
- GNLX 0.28
- MACD
- LUCD -0.00
- GNLX 0.02
- Stochastic Oscillator
- LUCD 28.57
- GNLX 85.64
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.